AI Article Synopsis
- Management of stage III non-small cell lung cancer (NSCLC) is complex and requires a coordinated, multidisciplinary approach due to its diverse nature.
- Recent advancements in treatment, like consolidation therapy with checkpoint inhibitors after chemo-radiotherapy and the use of tyrosine kinase inhibitors, have updated care standards significantly.
- The guidelines provided are evidence-based and crafted by thoracic oncology experts, addressing workup, staging, treatment, and follow-up to optimize patient care.
Article Abstract
Management of stage III non- small cell lung cancer (NSCLC) is very challenging due to being a group of widely heterogeneous diseases that require multidisciplinary approaches with timely and coordinated care. The standards of care had significant changes over the last couple of years because of the introduction of consolidation therapy with checkpoint inhibitor following concurrent chemo-radiotherapy and the evolving new role of tyrosine kinase inhibitors in the adjuvant setting. The manuscript presents evidence-based recommendations for the workup, staging, treatment and follow up of the various subtypes of stage III NSCLC. The guidelines were developed by experts in various fields of thoracic oncology and guidelines development. The guidelines consider the sequence of interventions and the role of each discipline in the management of the disease taking into account the recent development and included required resources to help physicians provide better care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.critrevonc.2020.103144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!